- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Placebo, TrIP-2D, TrIP-2SS, TrIP-2SS + Foradil
- Drug
- Lead sponsor
- Alkermes, Inc.
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Spartanburg, South Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 313–336
of 1,233
matching trials from the live ClinicalTrials.gov search.
- Conditions
- COPD (Chronic Obstructive Pulmonary Disease)
- Interventions
- Tiered whole health support for people living with COPD
- Behavioral
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- COPD, Chronic Obstructive Pulmonary Disease
- Interventions
- BIO-11006 Inhalation Solution, Placebo, BIO-11006
- Drug
- Lead sponsor
- BioMarck Pharmaceuticals, Ltd.
- Industry
- Eligibility
- 45 Years and older
- Enrollment
- 172 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 14
- States / cities
- Glendale, Arizona • Los Angeles, California • Bay Pines, Florida + 10 more
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- CTX-100 (formerly ETX-100) (hyaluronic acid)
- Drug
- Lead sponsor
- Turino, Gerard, M.D.
- Individual
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 3
- States / cities
- Tucson, Arizona • New York, New York
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- NVA237, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 440 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 54
- States / cities
- Homewood, Alabama • Jasper, Alabama • *See Various Dept.'s*, Arizona + 43 more
- Conditions
- COPD
- Interventions
- PrO2, Threshold Inspiratory Muscle Trainer
- Device
- Lead sponsor
- Miami VA Healthcare System
- Federal
- Eligibility
- 40 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Educational brochures
- Behavioral
- Lead sponsor
- VA Midwest Health Care Network
- Federal
- Eligibility
- Not listed
- Enrollment
- 4,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Obstructive Sleep Apnea, Chronic Obstructive Pulmonary Disease
- Interventions
- CPET
- Diagnostic Test
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 2
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- COPD
- Interventions
- Ensifentrine (formerly RPL554) 0.375 mg twice daily plus placebo, in addition to tiotropium, Ensifentrine (formerly RPL554) 0.75 mg twice daily plus placebo, in addition to tiotropium, Ensifentrine (formerly RPL554) 1.5 mg twice daily plus placebo, in addition to tiotropium, Ensifentrine (formerly RPL554) 3.0 mg twice daily plus placebo, in addition to tiotropium, Ensifentrine (formerly RPL554) placebo twice daily, in addition to tiotropium
- Drug
- Lead sponsor
- Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 416 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 50
- States / cities
- Anniston, Alabama • Fullerton, California • Los Angeles, California + 44 more
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD), Emphysema
- Interventions
- Home Based Pulmonary Rehabilitation
- Behavioral
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 40 Years to 99 Years
- Enrollment
- 375 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 3
- States / cities
- Jacksonville, Florida • Minneapolis, Minnesota • Rochester, Minnesota
- Conditions
- Asthma, Copd, Acute Exacerbation of COPD
- Interventions
- Inhaler Trainer System, Initial Inhaler Use Assessment, Inhaler Use Instruction
- Device · Other
- Lead sponsor
- Koronis Biomedical Technologies
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Non-Interventional Study
- Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 40 Years to 99 Years
- Enrollment
- 10,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Wilmington, Delaware
- Conditions
- Pulmonary Disease, Chronic Obstructive, Cigarette Smoking, Telemedicine
- Interventions
- smoking cessation, early COPD detection, electronic visit, Treatment As Usual
- Behavioral · Other
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- COPD
- Interventions
- Usual Care Pulmonary Rehabilitation Program, Pulmonary Rehabilitation Software-Based Home Program
- Other
- Lead sponsor
- Blue Marble Rehab Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 4
- States / cities
- Charlotte, North Carolina • Durham, North Carolina • Dawes, West Virginia + 1 more
- Conditions
- COPD
- Interventions
- Targeted Lung Denervation (TLD), Optimal Medical Care
- Device · Other
- Lead sponsor
- Nuvaira, Inc.
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 464 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Sacramento, California + 17 more
- Conditions
- Cachexia
- Interventions
- Placebo comparator, SUN11031 20 μg/kg, SUN11031 40 μg/kg
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 227 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 11
- States / cities
- Waterbury, Connecticut • Clearwater, Florida • Largo, Florida + 8 more
- Conditions
- COPD, Emphysema
- Interventions
- tiotropium
- Drug
- Lead sponsor
- Gelb, Arthur F., M.D.
- Individual
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 1
- States / cities
- Lakewood, California
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Fluticasone Furoate 100mcg / GW642444 (vilanterol) 25mcg, Fluticasone Propionate 250mcg/ salmeterol 50mcg
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 519 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Orlando, Florida • Atlanta, Georgia + 9 more
- Conditions
- Emphysema, COPD
- Interventions
- IBV® Valve System
- Device
- Lead sponsor
- Olympus Corporation of the Americas
- Industry
- Eligibility
- 40 Years to 74 Years
- Enrollment
- 277 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2017
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Los Angeles, California • Mission Viejo, California + 29 more
- Conditions
- COPD Exacerbation Acute
- Interventions
- Trimethoprim Sulfamethoxazole, Placebo
- Drug
- Lead sponsor
- Corewell Health East
- Other
- Eligibility
- 40 Years to 89 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Royal Oak, Michigan
- Conditions
- COPD, Pulmonary Hypertension, Exercise, Right Ventricular (RV) Dysfunction, Exercise Training
- Interventions
- Exercise training
- Behavioral
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Metastatic Cancer, Congestive Heart Failure, Chronic Obstructive Pulmonary Disease, Parkinson Disease, Interstitial Lung Disease, Amyotrophic Lateral Sclerosis, End Stage Liver Disease, End Stage Renal Disease, Diabetes Complications
- Interventions
- Respecting Choices First Steps, Five Wishes Form
- Behavioral
- Lead sponsor
- Duke University
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 790 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 4
- States / cities
- Birmingham, Alabama • Atlanta, Georgia • Columbia, South Carolina + 1 more
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Exercise
- Other
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- Not listed
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 1
- States / cities
- Westwood, Los Angeles, California
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Mobile spirometer, Device sensor, Salbutamol, Activity monitor, electronic diary card, CAT, ACT
- Device · Drug · Other
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 194 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Danville, Pennsylvania